Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Rhea-AI Summary

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its fourth quarter and full year 2024 financial results release for March 3, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:30 a.m. ET the same day.

Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 1983976. A webcast will be available through the investor relations section of Stereotaxis' website, and a phone replay will be accessible for one month after the call.

The company's technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Positive

• Technology has been used to treat over 150,000 patients globally

Negative

• None.

ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2024 fourth quarter and full year on Monday, March 3, 2025 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. ET that day to discuss the Company’s results and corporate developments.

What:	Stereotaxis fourth quarter and full year 2024 financial results conference call
When:	Monday, March 3, 2025 at 8:30 a.m. ET (5:30 a.m. PT)
Dial In Number:	To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 1983976.
Webcast:	To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
Call Replay:	A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis

Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:
David L. Fischel
Chairman and Chief Executive Officer
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

FAQ

When will Stereotaxis (STXS) release Q4 and full year 2024 earnings?

Stereotaxis will release its Q4 and full year 2024 financial results on Monday, March 3, 2025, before the U.S. financial markets open.

How can investors join the STXS Q4 2024 earnings call?

Investors can join by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 1983976, or access the webcast through Stereotaxis' investor relations website.

What time is the Stereotaxis (STXS) Q4 2024 earnings call?

The earnings conference call and webcast will take place at 8:30 a.m. ET (5:30 a.m. PT) on Monday, March 3, 2025.

How many patients have been treated with Stereotaxis (STXS) technology?

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions.